GlassScriptPhysician profile
Semira Ramic
NPI 1205274669
$1,308.47
in general payments reported to CMS, 2019-2025
19 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $90.30 · 2021: $132 · 2022: $57.02 · 2023: $242 · 2024: $203 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.46 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $404.70 | 2019-2025 | Tysabri, Vumerity |
| Abbvie INC. | $354.82 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $54.13 | 2024-2025 | Austedo Xr, Ajovy |
| Argenx US, INC. | $50.71 | 2023-2025 | Vyvgart |
| Neurelis, INC. | $50.53 | 2020-2021 | |
| Lilly USA, LLC | $48.85 | 2019-2024 | Emgality, Reyvow, Kisunla |
| Tanabe Pharma America, INC. | $44.63 | 2019-2021 | |
| Allergan, INC. | $44.08 | 2019-2020 | |
| Genentech USA, INC. | $39.11 | 2025 | Ocrevus Zunovo |
| Ucb, INC. | $38.28 | 2024 | Rystiggo |
| Sk Life Science, INC. | $31.68 | 2020-2024 | |
| Boston Scientific Corporation | $26.67 | 2021 | |
| Medtronic, INC. | $22.29 | 2023 | Activa PC |
| Catalyst Pharmaceuticals, INC. | $20.33 | 2024 | |
| Eisai INC. | $19.70 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $17.12 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.09 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Semira Ramic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.